GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Fresenius Medical cuts top end of 2026 profit outlook - Finance news and analysis from Global Banking & Finance Review
Finance

Fresenius Medical cuts top end of 2026 profit outlook

Published by Global Banking & Finance Review

Posted on November 3, 2026

1 min read

· Last updated: November 3, 2026

Add as preferred source on Google

Fresenius Medical Trims 2026 Profit Outlook Citing Regulatory Headwinds

Fresenius Medical Care Lowers Profit Forecast Amid Regulatory and Inflation Challenges

Nov 3 (Reuters) - German dialysis specialist Fresenius Medical Care cut the upper end of its 2026 operating income outlook on Tuesday, citing regulatory and inflation headwinds after reporting third-quarter results.

Updated 2026 Operating Income Outlook

It now expects 2026 operating income to range from flat to a mid-single-digit percentage decline, compared with its previous forecast for a mid-single-digit percentage decline to a mid-single-digit increase.

Key Financial Highlights

  • Third-quarter operating income excluding special items fell 5% to €545 million ($610 million) from €574 million a year earlier, compared with Vara Research consensus of €518 million.
  • US same-market treatments declined 1.1%, accelerating from declines of 0.4% in the first quarter and 0.9% in the second quarter.
  • Revenue grew 1% to €4.94 billion from €4.89 billion a year earlier.
Leadership and Strategic Initiatives

The results come weeks after Shervin J. Korangy became CEO as FMC seeks to revive growth following years of restructuring efforts.

Currency Exchange Rate

($1 = 0.8937 euros)

(Reporting by Kira Britten and Paolo Laudani, editing by Bartosz Dabrowski)

Key Takeaways

  • Q3 operating income excluding special items fell 5% to €545 million vs. €574 million a year earlier, beating consensus of €518 million (freseniusmedicalcare.com)
  • U.S. same‑market treatments dropped 1.1%, down from earlier declines, while revenue rose 1% to €4.94 billion (freseniusmedicalcare.com)
  • New CEO Shervin J. Korangy, just three weeks into his role, emphasized the company’s structural transformation and innovation focus amid headwinds (freseniusmedicalcare.com)

References

Tags

Related Articles

More from Finance

Explore more articles in the Finance category